Fosamax Femur Fracture Lawsuit
Fosamax®, Boniva®, and Reclast® lawsuits combined into one MDL

Fosamax, Boniva, and Reclast medications are all included in a class of drugs referred to as “bisphosphonates,” which are designed to strengthen weaken bones. These drugs are often prescribed to patients who suffer from osteoporosis, a chronic condition in which bone tissue becomes weakened.

The most commonly taken bone strengthening medication in the U.S. is Fosamax, which was introduced by Merck & Co. in 1995.

Years after its release, reports were filed claiming that Fosamax causes femur fractures and victims began to file Fosamax lawsuits. These cases were consolidated as part of a multidistrict litigation (MDL) in the U.S. District Court for the District of New Jersey before Judge Garrett E. Brown for pretrial proceedings.

In addition to Fosamax litigation, femur fracture lawsuits were filed against the manufacturers of Boniva and Reclast including similar allegations that these drugs also cause femur fractures. All Boniva and Reclast lawsuits will be transferred to the Fosamax litigation and consolidated into one large MDL.

About 6 cases have already been transferred to the Fosamax MDL. One of which was filed by a woman who claims she suffered femur fractures from her use of Fosamax, Boniva, and Reclast.

Merck currently faces more than a thousand lawsuits filed by women who claim Fosamax causes femur fractures. Three Fosamax bellwether trials have been scheduled for this year and will aid in indicating future trends for upcoming lawsuits.

The Food and Drug Administration issued new warning labels for all bisphosphonate medications to include the risk for suffering bone injuries and femur fractures injuries. Women who have taken any of these medications are encouraged to seek medical attention if, after taking any of the medications, they experience groin pain or thigh pain as this may be a sign of a coming fracture.


About the Contributor

Related Posts